Trimi is one of the price leaders in compounded GLP-1 telehealth — its advertised $99/month semaglutide is among the lowest numbers in the category, and like Pallas it runs asynchronous care with no membership fee and flat pricing across doses. The comparison here isn't really about features; it's about what the low number requires (an annual prepay), what Trimi doesn't offer (a brand tier), and what you can verify about each platform before paying.
Pricing on both sides changes often; figures reflect each platform's published pricing as of August 2026 — confirm current numbers on both sites before signing up.
The three differences that matter most
- The headline price is an annual-prepay rate. Trimi's $99/month semaglutide and $125/month tirzepatide require paying a year up front ($1,188 and $1,500). Month-to-month, Trimi runs $175 and $235 — still below Pallas's per-month averages, and we'll say that plainly. Pallas's compounded semaglutide injection is $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Tirzepatide is $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. No prepay tier exists at Pallas: the published rate is the only rate.
- Orders and bundles are final at Trimi. Per Trimi's published policy, you get a full refund if a clinician doesn't approve you — but once a prescription is issued, the order is final, and multi-month bundles aren't pro-rated (early exits are reviewed case-by-case). Pallas charges nothing until a clinician prescribes, and plans cancel anytime, self-serve, with no bundle to unwind.
- The brand tier and the paper trail. Trimi is compounded-only — no FDA-approved brand pens — and its site doesn't publish a legal entity name or street address. Pallas dispenses both tiers (brand pens cash-pay, $499 for the first month and then from $599/month) and publishes its clinical leadership.
About compounded medications
Compounded medications are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy. A licensed clinician decides whether a compounded preparation — for example, a dose level or a formulation a brand-name product doesn't offer — is appropriate for you.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.
Quick comparison
| Pallas Health | Trimi | |
|---|---|---|
| Compounded semaglutide injection | Yes — one all-in price | Yes — $175/mo month-to-month; $99/mo on 12-month prepay |
| Compounded tirzepatide injection | Yes — one all-in price | Yes — $235/mo month-to-month; $125/mo on annual prepay |
| FDA-approved brand (Wegovy®, Zepbound®) | Yes — $499 first month, then from $599/mo, cash-pay | Not offered |
| Membership fee | None | None |
| Price changes as your dose increases | No — flat at every dose | No, per their pledge |
| If a clinician doesn't prescribe | Nothing charged | Full refund |
| After a prescription is issued | Cancel your plan anytime | "The order is final" per their policy; bundles not pro-rated |
| Care delivery | 100% online, async in most states | 100% online, async |
| Published legal entity / address | Yes | Not published on their site |
| Companion app | Free on iOS and Android, no subscription | Not offered |
| Year founded | 2026 | 2024 |
What Trimi does well
Price leadership — genuinely. Month-to-month, Trimi undercuts Pallas on both medications; on annual prepay it undercuts nearly everyone. Free overnight shipping is included, there's no membership fee, pricing is flat across doses, and pay-over-time options (Klarna and similar) are displayed. If your only axis is the monthly number and you're comfortable with the terms, Trimi prices sharply.
A conditional outcome promise. Trimi offers a 6-month money-back promise — plan fees refunded if you have no net weight loss after six continuous months, subject to adherence and logging requirements and a 30-day claim window. Read the conditions; it's a real, if narrow, backstop.
Simple async care. Like Pallas, Trimi runs a no-video-visit intake with fast provider review and portal messaging, and it names its 503A pharmacy partners on its site.
What Pallas does differently
Both tiers, one platform. Trimi can only ever prescribe compounded medication. Pallas dispenses FDA-approved Wegovy®, Ozempic®, Zepbound®, and Mounjaro® alongside clinician-personalized compounded injections — so if a brand becomes the right fit later, you don't switch platforms. The compounded plans are compounded semaglutide and compounded tirzepatide injections, one price with clinician care included.
No prepay, no order lock. Pallas's rate requires no $1,188 annual commitment, and there's no order-final clause: nothing charged unless a clinician prescribes, cancel anytime after.
Verifiability. Pallas publishes who it is — legal entity, clinical leadership, named reviewers. Whatever platform you consider, verify the same three things: LegitScript status, clinician licensure in your state, and US-licensed pharmacy sourcing.
A self-serve portal and free app. Orders, refills, plan switches, billing, and anytime provider messaging in one portal, plus the free Pallas companion app (iOS and Android) for protein, steps, weight trend, and dose reminders.
Who should pick which
Trimi is probably the better fit if:
- The monthly number is your deciding factor — its month-to-month rates undercut Pallas, and its annual prepay goes lower still
- You're confident enough in your plan to prepay a year and accept order-final terms
- You only want compounded therapy and won't need a brand-name option
Pallas is probably the better fit if:
- You may want brand-name medication now or later — Trimi doesn't offer it
- You want no prepay, no order lock, and cancel-anytime terms
- Published company identity and verifiable certification matter to your decision
- You want DC coverage and a free companion app
Switching between them
Bring your medication name, current dose, and titration history. If you're mid-bundle at Trimi, check its case-by-case early-exit policy first — bundles aren't pro-rated. A Pallas clinician picks up from your current dose — no restart of titration unless you've been off medication for more than four weeks. For the clinical side of choosing between molecules, see semaglutide vs tirzepatide.
Bottom line: Trimi wins the price column — and across the board — with an annual prepay unlocking the lowest rates and order-final terms once a prescription exists. Pallas answers with everything around the price: a brand-name tier Trimi doesn't have, no prepay commitment, nothing charged until a clinician prescribes, cancel-anytime flexibility, published company identity, and certification you can verify yourself. If the monthly number decides it, Trimi's is lower; if optionality and verifiability decide it, that's the Pallas side.
